South Rampart Pharma Issued Composition of Matter Patent for Novel Non-Toxic Treatment for Pain
Oct. 4, 2022 - New patent grant further secures South Rampart's
South Rampart Pharma Receives Year 3 of NIH Fast-Track STTR Commercialization Grant
Sept. 22, 2022 South Rampart Pharma ("South Rampart" or the
South Rampart Pharma Announces Late-Breaking Presentation at IASP 2022 World Congress on Pain
Aug. 25, 2022 South Rampart Pharma ("South Rampart" or the
South Rampart Pharma Announces Appointment of Josh Blacher as Chief Financial Officer
Aug. 16, 2022 South Rampart Pharma ("South Rampart" or the
South Rampart Pharma Achieves Development Milestone and Advances to Phase II of Active NIH Fast-Track STTR Commercialization Award
May 4, 2022 $1.9 million NIH fast-track STTR grant fuels
South Rampart Pharma Announces Patient Enrollment and Dosing Underway in Phase 1 Study Evaluating Novel Non-Opioid Approach to Pain with Lead Program, SRP-3D (DA)
March 23, 2022 SRP-3D (DA) has demonstrated a compelling safety
NIH STTR Grant To Fast Track New Class Of Pain Reliever Without Addiction Or Toxicity
Sep 25, 2020 The National Institute of Neurological Disorders and
South Rampart Pharma Identifies New Class of Non-Opioid Pain Medicines in European Journal of Medicinal Chemistry Publication
July 10, 2020 South Rampart Pharma, LLC (“South Rampart” or
LSU Health New Orleans Discovers New Class of Safer Analgesics
Jul 6, 2020 Researchers at LSU Health New Orleans Neuroscience